Home Alzheimer’s Disease Carfilzomib Triplet Therapy Shows Inferior PFS in Newly Diagnosed Multiple Myeloma

Carfilzomib Triplet Therapy Shows Inferior PFS in Newly Diagnosed Multiple Myeloma

Carfilzomib (Kyprolis) combined with lenalidomide (Revlimid) and dexamethasone (Decadron; KRd) failed to improve progression-free survival (PFS), compared with the current standard of care triplet of bortezomib (Velcade), lenalidomide, and dexamethasone (VRd), in patients with newly diagnosed multiple myeloma, according to results of the ENDURANCE (E1A11) trial presented ahead of the 2020 ASCO Virtual Scientific Program.

As a result, researchers have determined that VRd remains the superior triplet induction regimen in this patient population, making it a suitable backbone for 4-drug combinations as well.

Given the higher efficacy of carfilzomib seen in recent phase II trials, investigators sought to determine if carfilzomib could replace bortezomib in the current standard of care triplet induction regimen in standard and intermediate risk newly diagnosed multiple myeloma.

To do so,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments